Extended CSF cytarabine exposure following intrathecal administration of DTC 101.
about
Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabineLipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.Carcinomatous Meningitis from Unknown Primary Carcinoma.Intrathecal liposomal cytarabine: more friend than foe?Liposomal Formulations in Clinical Use: An Updated Review.Clinical pharmacology of encapsulated sustained-release cytarabine.Lipid-based slow-release formulation of amikacin sulfate reduces foreign body-associated infections in mice.Liposomal cytarabine in the prophylaxis and treatment of CNS lymphoma: toxicity analysis in a retrospective case series study conducted at Polish Lymphoma Research Group CentersRandomized trial of radiation-free central nervous system prophylaxis comparing intrathecal triple therapy with liposomal cytarabine in acute lymphoblastic leukemiaNeoplastic meningitis resulting from hematological malignancies: pharmacokinetic considerations and maximizing outcomeTreatment of neoplastic meningitis: what is the standard of care?Science and technology of the emerging nanomedicines in cancer therapy: A primer for physicians and pharmacists.A review of leptomeningeal metastases in pediatrics.Improving nucleoside analogs via lipid conjugation: Is fatter any better?Carcinomatous meningitis: Leptomeningeal metastases in solid tumorsCentral nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trialEvaluation of osmolality and pH of various concentrations of methotrexate, cytarabine, and thiotepa prepared in normal saline, sterile water for injection, and lactated Ringer's solution for intrathecal administration.Treatment of lymphomatous and leukemic meningitis with liposomal encapsulated cytarabine.Optimal management of brain metastases from breast cancer. Issues and considerations.Acute painful lumbosacral paresthesia after intrathecal rituximabPediatric leptomeningeal metastases: outcome following combined therapy.The Multirole of Liposomes in Therapy and Prevention of Infectious Diseases.Nucleobase and Nucleoside Analogues: Resistance and Re-Sensitisation at the Level of Pharmacokinetics, Pharmacodynamics and MetabolismVentriculoperitoneal Shunts Equipped with On-Off Valves for Intraventricular Therapies in Patients with Communicating Hydrocephalus due to Leptomeningeal Metastases
P2860
Q28346742-E3DFB116-0DC7-41C3-B2DF-A5A4F69F0CFAQ30366990-5DBD894F-9CA7-44FA-A946-6E48A493EBB0Q30479900-CE2ECF95-C3EA-46A0-8CA0-55EBD4E1E633Q33577149-C51D51F7-761B-44D0-B2DC-605410578D62Q33850427-6614A52A-E074-49E8-9150-3D8522350914Q34072145-227254A7-226B-4BB4-B6D8-975A31ACC3BCQ35117209-00363D07-190F-4E29-B20C-580E56859A6EQ35123219-D633A105-A8EA-44E7-AB96-F8E15D82B37CQ35669875-E997B9CF-AA15-4568-9A7D-4C085CAE38B7Q35799389-D900F534-3653-4DEF-AA99-AD03BD1A3E77Q36107024-05D3D28E-B11A-452A-8495-CF78146EABF4Q36394925-122572B1-0F03-4A9B-966F-FE1907F03B85Q36690632-ACEEE8AA-7B6E-4CAA-98CD-1DE4BFB2576BQ36706248-AAB98347-BC65-4857-A4DC-4F2DB1C56236Q36851197-4359CFE9-CFED-4DC9-9AA2-CC4FF3F75951Q36859222-F9BDA471-95B8-42BC-AD66-6298BB6EA52BQ37261066-AEC812F0-8D38-45E9-8845-A881A31DE629Q37428802-8181CD99-0BA2-4D4D-AEFC-7AD01B3EFAB6Q38067340-14827407-019C-4E89-BFD4-46FDAC1BC13CQ42594041-6076093B-1946-4F46-B01A-1A6E67B4F3D2Q46024534-AF7B2E40-FE22-487B-9EFD-C02F8CEC6600Q50124824-BFE0FB90-618F-4294-8156-AD9AF4B005B6Q57175017-4EF8A589-F6FE-4338-9345-4613D31127CFQ58780721-96DEFB24-04BB-464A-9B6B-49DA667DAEC6
P2860
Extended CSF cytarabine exposure following intrathecal administration of DTC 101.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年学术文章
@wuu
1993年学术文章
@zh
1993年学术文章
@zh-cn
1993年学术文章
@zh-hans
1993年学术文章
@zh-my
1993年学术文章
@zh-sg
1993年學術文章
@yue
1993年學術文章
@zh-hant
name
Extended CSF cytarabine exposure following intrathecal administration of DTC 101.
@en
Extended CSF cytarabine exposure following intrathecal administration of DTC 101.
@nl
type
label
Extended CSF cytarabine exposure following intrathecal administration of DTC 101.
@en
Extended CSF cytarabine exposure following intrathecal administration of DTC 101.
@nl
prefLabel
Extended CSF cytarabine exposure following intrathecal administration of DTC 101.
@en
Extended CSF cytarabine exposure following intrathecal administration of DTC 101.
@nl
P2093
P1476
Extended CSF cytarabine exposure following intrathecal administration of DTC 101
@en
P2093
P304
P356
10.1200/JCO.1993.11.11.2186
P407
P50
P577
1993-11-01T00:00:00Z